article thumbnail

Is the launch environment really more competitive now?

pharmaphorum

It’s often stated – mostly without reference to data – that the environment for innovative launches is more competitive now than it ever has been. A second, “transitional era” from 2000-2015 was one of older specialty products, including those in multiple sclerosis, early immunological biologics, and oncologics.

article thumbnail

Harnessing the Power of Generational Diversity as a Competitive Advantage

PM360

Today’s workforce includes Traditionalists (born 1927-1945), Boomers (1946-1964), Gen X (1965-1980), Millennials (1981-1996), and Gen Z (1997-2015). Marketing and comms teams that go beyond simply accepting generational differences by leveraging them proactively will lead to increased engagement, innovation, and organizational success.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharma is big business whose goal is to maximize shareholder value

World of DTC Marketing

From 2016 to 2020, the 14 leading drug companies spent $577 billion on stock buybacks and dividends—$56 billion more than they spent on R&D over the same period.” In a 2015 study of 36 cancer drugs that had recently been approved, only 5 showed extended life. Big pharma is big business. Here’s another example.

Pharma 292
article thumbnail

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

Impetus Digital

Increased competition and evolving standard of care New competitors are entering the market at a rapid pace, and competition is intensifying. This competitive intensity tends to focus on smaller patient populations with multiple treatment options (1,2). However, with rapid growth comes growing pains.

article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

Observational studies should not be seen as competition to RCTs but as complementary to them, and as a sector we need to stop working in silos and develop an integrated and more comprehensive approach to evidence-based decision-making in safeguarding public health. Guide on Methodological Standards in Pharmacoepidemiology (Revision 11).

Safety 109
article thumbnail

Comparison of Humira biosimilars in the US and Europe

Pharmaceutical Technology

Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. Until 2010, no regulatory approval pathway for biosimilars existed in the US and the first biosimilar was only approved in the US in 2015. The biosimilar market in the US may progress differently this time.

article thumbnail

Is the pharmaceutical sector realising its potential for sustainable manufacturing?

European Pharmaceutical Review

Globally, the pharmaceutical sector emitted around 52 megatonnes of CO 2 in 2015, the most recent period for which detailed numbers are available. Creating more sustainable business processes is a pre-competitive activity; we all win when we make progress in sustainability and lose if we don’t. References Belkhir L, Elmeligi A.